Advertisement

Topics

Latest "Amphivena Therapeutics" News Stories - Page: 5

20:54 EDT 25th March 2019 | BioPortfolio

Here are the most relevant search results for "Amphivena Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Amphivena Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Amphivena Therapeutics for you to read. Along with our medical data and news we also list Amphivena Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Amphivena Therapeutics Companies for you to search.

Showing "Amphivena Therapeutics" News Articles 101–125 of 7,800+

Probably Relevant

BriaCell Therapeutics announces positive proof of concept data in treating breast cancer

Briacell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V) CEO William Williams speaks with Proactive Investor's Christine Corrado at the MicroCap Conference in New York. BriaCell Therapeutics Corp. is an immuno-oncology company which develops immunotherapy treatments for cancer. BriaCell is currently focused on the clinical development of Bria-IMT™ as a 2nd line treatment for patients with adva...


e-Therapeutics (ETX) - Keeping the faith

Edison Investment Research - Pharmaceutical & healthcare - e-Therapeutics: e-Therapeutics’ (ETX) H118 results were a routine financial update highlighting its continuing focus on partnering the Network-driven Drug Discovery (NDD) platform, out-licensing its NDD-derived preclinical immunoncology (I/O) assets and financial prudence. The H118 operating loss was £2.8m. Cash outflow was &po...

Horizon Pharma and HemoShear Therapeutics Enter Exclusive Drug Discovery Collaboration in Gout

DUBLIN & CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–Horizon Pharma plc (Nasdaq: HZNP) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a collaboration to discover and develop novel therapeutics for gout. “As we continue to grow our pipeline, we are committed to addressing unmet treatment needs for people with gout as well as solidifying our leade...


Astellas buys Potenza Therapeutics for up to $405m

Japanese pharmaceutical company Astellas Pharma has acquired US-based Potenza Therapeutics for a total consideration of up to $405m. The deal...Read More... The post Astellas buys Potenza Therapeutics for up to $405m appeared first on Pharmaceutical Technology.

Nestle Health increases stake in Aimmune Therapeutics

Nestlé Health Science has raised its equity stake in biopharmaceutical firm Aimmune Therapeutics to around 19% with an investment of...Read More... The post Nestle Health increases stake in Aimmune Therapeutics appeared first on Pharmaceutical Technology.

Realm Therapeutics Provides Update on Strategic Review

MALVERN, Pa., Nov. 29, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized Read more...

Health Canada approves United Therapeutics' neuroblastoma drug

United Therapeutics' PrUnituxin, or dinutuximab, in combination with granulocyte-macrophage colony-stimulating factor, interl -More- 

Executives On The Move: CEOs Welcomed At Cadent Therapeutics And Enzyvant Sciences, And Top Development Spot Filled At Bicycle Therapeutics

A new CEO for movement and cognitive disorder company Cadent Therapeutics, and Alexion SVP departs for CEO position at rare...   

Kite partners with HiFiBiO Therapeutics for TCR-based cancer therapies

Gilead Sciences’ subsidiary Kite has signed a research collaboration and licence agreement with biotechnology company HiFiBiO Therapeutics to help develop...Read More... The post Kite partners with HiFiBiO Therapeutics for TCR-based cancer therapies appeared first on Pharmaceutical Technology.

Beam Therapeutics raises $135m to advance CRISPR technologies

US-based precision genetic medicines developer Beam Therapeutics has raised $135m in a series B funding round to drive the development...Read More... The post Beam Therapeutics raises $135m to advance CRISPR technologies appeared first on Pharmaceutical Technology.

Pluristem Therapeutics (PSTI) - Termination of coverage

Edison Investment Research - Pharmaceutical & healthcare - Pluristem Therapeutics: Edison Investment Research is terminating coverage on Pluristem Therapeutics (PSTI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. ISIN: US72940R1023

AELIX Therapeutics and Gilead Sciences to trial HIV therapy

AELIX Therapeutics and Gilead Sciences have entered a joint clinical research collaboration for the analysis of proprietary investigational products. Called AELIX-003,...Read More... The post AELIX Therapeutics and Gilead Sciences to trial HIV therapy appeared first on Drug Development Technology.

Maze Therapeutics launches with $191m financing

Maze Therapeutics has secured an initial investment commitment of $191m, led by Third Rock Ventures and ARCH Venture Partners. GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments and The post Maze Therapeutics launches with $191m financing appeared first on Pharmaceutical Business review.

PTA-News: Rapid Dose Therapeutics Inc.: FLOWER -2-

DJ PTA-News: Rapid Dose Therapeutics Inc.: FLOWER ONE GEHT ERSTE LIZENZVEREIBARUNG ZUR NUTZUNG DER MARKENRECHTE UND PARTNERSCHAFT MIT RAPID DOSE THERAPEUTICS EIN - FLOWER ONE BRINGT DAS INNOVATIVE ...

Gilead partners with Tango Therapeutics to develop new cancer drugs

US-based Gilead Sciences has formed a strategic alliance with Tango Therapeutics for the discovery, development and commercialisation of new targeted...Read More... The post Gilead partners with Tango Therapeutics to develop new cancer drugs appeared first on Pharmaceutical Technology.

iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - February 25, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a total of 14...

iCo Therapeutics Inc. Announces the Issuance of 4,000,000 Units Pursuant to its C$750,000 Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - February 11, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a total of 4,...

iCo Therapeutics Provides Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - October 2, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced several positive corporate developments and u...

AstraZeneca and Seres Therapeutics to study new cancer therapy process

AstraZeneca has formed a research alliance with US-based Seres Therapeutics to explore the use of microbiome in boosting the efficacy...Read More... The post AstraZeneca and Seres Therapeutics to study new cancer therapy process appeared first on Pharmaceutical Technology.

AstraZeneca and Seres Therapeutics to study new cancer therapy approach

AstraZeneca has formed a research alliance with US-based Seres Therapeutics to explore the use of microbiome in boosting the efficacy...Read More... The post AstraZeneca and Seres Therapeutics to study new cancer therapy approach appeared first on Pharmaceutical Technology.

Novo Nordisk and e-therapeutics alliance to focus on type-2 diabetes

Novo Nordisk has entered into research collaboration with UK-based E-therapeutics for the development of new treatment strategies for a specific...Read More... The post Novo Nordisk and e-therapeutics alliance to focus on type-2 diabetes appeared first on Pharmaceutical Technology.

InvaGen to acquire Avenue Therapeutics for $215m

InvaGen Pharmaceuticals, a unit of India-based Cipla, has signed definitive agreements to buy US-based specialty pharmaceutical firm Avenue Therapeutics for...Read More... The post InvaGen to acquire Avenue Therapeutics for $215m appeared first on Pharmaceutical Technology.

Maze Therapeutics raises $191m to support genetic research

Maze Therapeutics, a start-up with focus on translating genetic insights into new medicines, has been launched operations in the by...Read More... The post Maze Therapeutics raises $191m to support genetic research appeared first on Pharmaceutical Technology.

Roche subsidiary Genentech to acquire Jecure Therapeutics

Swiss firm Roche Group’s affiliate Genentech has agreed to acquire US biotechnology company Jecure Therapeutics to strengthen its position in...Read More... The post Roche subsidiary Genentech to acquire Jecure Therapeutics appeared first on Pharmaceutical Technology.

Allergy Therapeutics delivers “stronger than expected” first-half growth as it awaits PQ Birch trial data

Allergy Therapeutics is a long-established specialist in the prevention, diagnosis and treatment of allergies


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks